Stockreport

AC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimer’s Disease

AC Immune SA  (ACIU) 
Last ac immune sa earnings: 11/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: acimmune.com/en/investors
PDF Decision follows Independent Data Monitoring Committee analysisThe Alzheimer’s Prevention Initiative (API) study of crenezumab in familial Alzheimer’s disease continuesT [Read more]